# Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

> **NCT00066989** · PHASE2 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 200 (—)

## Conditions studied

- Staphylococcal Infections

## Interventions

- **DRUG:** Staphylococcus aureus Immune Globulin (Human) 5%

## Key facts

- **NCT ID:** NCT00066989
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2004-08
- **Final completion:** 2004-08
- **Target enrollment:** 200 (—)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066989, "Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00066989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*